Skip to content
Search

Latest Stories

Pandemic-hit India says UAE is Plan B for T20 World Cup

This year's Twenty20 World Cup could be moved to the United Arab Emirates if the COVID-19 crisis does not subside in India, the country's cricket board said.

Six months before the showpiece's scheduled start, India reported a record 386,452 new cases on Friday, though medical experts believe actual numbers may be five to 10 times greater.


The governing International Cricket Council (ICC) said this month it was sticking to hosting the event in India but had back-up plans, without specifying an alternative location.

"It would be the UAE," Board of Control for Cricket in India (BCCI) general manager Dhiraj Malhotra told the BBC on Thursday.

"...We'll take the tournament there, but it'll still be done by the BCCI," added Malhotra, also the tournament director.

He did not respond to calls and messages to elaborate, but an ICC spokesman confirmed the plan.

The governing body is monitoring the progress of the Indian Premier League, which is continuing in the midst of the epidemic. "It is too early to make a call," the spokesman told Reuters.

The pandemic forced the Indian board to stage last year's IPL in the UAE.

The BCCI last year signed a hosting agreement with the Emirates Cricket Board (ECB).

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less